Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs
Not yet recruiting · NCT07578467 · Registry updated 2026-07-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | DNA Virus Infections, Disease Attributes, Genital Diseases, Infections, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, Urogenital Diseases, carcinoma, epithelial neoplasm, human papilloma virus infection, infectious disease, neoplasm, sexually transmitted disease, squamous cell carcinoma, squamous cell neoplasm, viral infectious disease, viral sexually transmitted disease | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-08 | NCT07578467 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Abramson Cancer Center at Penn Medicine | 137 |
| Aprea Therapeutics | 3 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||